重组人促红细胞生成素通过 Jak2 介导的Src 激活和 PTEN 失活拮抗曲妥珠单抗治疗乳腺癌细胞。
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.
机构信息
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
出版信息
Cancer Cell. 2010 Nov 16;18(5):423-35. doi: 10.1016/j.ccr.2010.10.025.
Abstract
We found that the receptor for erythropoietin (EpoR) is coexpressed with human epidermal growth factor receptor-2 (HER2) in a significant percentage of human breast tumor specimens and breast cancer cell lines. Exposure of HER2 and EpoR dual-positive breast cancer cells to recombinant human erythropoietin (rHuEPO) activated cell signaling. Concurrent treatment of the cells with rHuEPO and trastuzumab reduced the cells' response to trastuzumab both in vitro and in vivo. We identified Jak2-mediated activation of Src and inactivation of PTEN as underlying mechanisms through which rHuEPO antagonizes trastuzumab-induced therapeutic effects. Furthermore, we found that compared with administration of trastuzumab alone, concurrent administration of rHuEPO and trastuzumab correlated with shorter progression-free and overall survival in patients with HER2-positive metastatic breast cancer.
摘要
我们发现，促红细胞生成素受体（EpoR）在相当一部分人类乳腺癌标本和乳腺癌细胞系中与人类表皮生长因子受体-2（HER2）共表达。HER2 和 EpoR 双阳性乳腺癌细胞暴露于重组人促红细胞生成素（rHuEPO）可激活细胞信号转导。同时用 rHuEPO 和曲妥珠单抗治疗这些细胞，可在体外和体内降低细胞对曲妥珠单抗的反应。我们确定 Jak2 介导的Src 激活和 PTEN 失活是 rHuEPO 拮抗曲妥珠单抗诱导的治疗效果的潜在机制。此外，我们发现与单独使用曲妥珠单抗相比，HER2 阳性转移性乳腺癌患者同时使用 rHuEPO 和曲妥珠单抗与无进展生存期和总生存期缩短相关。
相似文献
1
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.重组人促红细胞生成素通过 Jak2 介导的Src 激活和 PTEN 失活拮抗曲妥珠单抗治疗乳腺癌细胞。
Cancer Cell. 2010 Nov 16;18(5):423-35. doi: 10.1016/j.ccr.2010.10.025.
2
Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.Erythropoietin 受体表达及其与曲妥珠单抗反应和耐药性在 HER2 阳性乳腺癌细胞中的关系。
Breast Cancer Res Treat. 2012 Dec;136(3):739-48. doi: 10.1007/s10549-012-2316-x. Epub 2012 Nov 2.
3
Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.生长分化因子 15（GDF15）介导的 HER2 磷酸化降低了 HER2 过表达乳腺癌细胞对曲妥珠单抗的敏感性。
Biochem Pharmacol. 2011 Nov 1;82(9):1090-9. doi: 10.1016/j.bcp.2011.07.082. Epub 2011 Jul 23.
4
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.人表皮生长因子受体 2 过表达的局部晚期乳腺癌中磷酸酶和张力蛋白同系物缺失或磷酸肌醇-3 激酶激活以及对曲妥珠单抗或拉帕替尼的反应。
J Clin Oncol. 2011 Jan 10;29(2):166-73. doi: 10.1200/JCO.2009.27.7814. Epub 2010 Dec 6.
5
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.PI3K 通路激活导致曲妥珠单抗和拉帕替尼的疗效均降低。
BMC Cancer. 2011 Jun 15;11:248. doi: 10.1186/1471-2407-11-248.
6
Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models.在促红细胞生成素受体阳性乳腺癌模型中，重组促红细胞生成素不会刺激肿瘤生长。
Mol Cancer Ther. 2006 Feb;5(2):347-55. doi: 10.1158/1535-7163.MCT-05-0203.
7
Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.miR-21 的上调介导了乳腺癌对曲妥珠单抗治疗的耐药性。
J Biol Chem. 2011 May 27;286(21):19127-37. doi: 10.1074/jbc.M110.216887. Epub 2011 Apr 6.
8
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.PTEN、PIK3CA、p-AKT 和 p-p70S6K 状态：与曲妥珠单抗治疗 HER2 阳性转移性乳腺癌患者的反应和生存的相关性。
Am J Pathol. 2010 Oct;177(4):1647-56. doi: 10.2353/ajpath.2010.090885. Epub 2010 Sep 2.
9
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.与局部播散性乳腺癌和曲妥珠单抗耐药相关的致癌 HER2 异构体。
Mol Cancer Ther. 2009 Aug;8(8):2152-62. doi: 10.1158/1535-7163.MCT-09-0295. Epub 2009 Aug 11.
10
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.表皮生长因子受体（EGFR）和胰岛素样生长因子 1 受体（IGF1R）信号的增强，以及 PTEN/PI3K/Akt 通路的失调与曲妥珠单抗治疗 HER2 阳性乳腺癌的耐药性有关。
Br J Cancer. 2012 Apr 10;106(8):1367-73. doi: 10.1038/bjc.2012.85. Epub 2012 Mar 27.
引用本文的文献
1
HER2-Positive Breast Cancer Treatment and Resistance.人表皮生长因子受体2阳性乳腺癌的治疗与耐药性
Adv Exp Med Biol. 2025;1464:495-525. doi: 10.1007/978-3-031-70875-6_24.
2
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.促红细胞生成素刺激剂联合辅助抗 HER2 治疗对早期乳腺癌患者结局的影响：ALTTO 研究的亚分析。
Breast Cancer Res Treat. 2024 Feb;203(3):497-509. doi: 10.1007/s10549-023-07159-9. Epub 2023 Nov 8.
3
Resistance to Trastuzumab.对曲妥珠单抗的耐药性。
Cancers (Basel). 2022 Oct 19;14(20):5115. doi: 10.3390/cancers14205115.
4
Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.灭活扩增的 HER2：挑战、困境与未来方向。
Cancer Res. 2022 Aug 16;82(16):2811-2820. doi: 10.1158/0008-5472.CAN-22-1121.
5
Pan-Cancer Analysis Based on Expression With Potential Value in Prognosis and Tumor Immunity in 33 Tumors.基于33种肿瘤中表达情况的泛癌分析及其在预后和肿瘤免疫中的潜在价值
Front Oncol. 2022 Mar 14;12:844794. doi: 10.3389/fonc.2022.844794. eCollection 2022.
6
Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition.Src 家族激酶、衔接蛋白和上皮-间质转化中的肌动蛋白细胞骨架。
Cell Commun Signal. 2021 Jun 30;19(1):67. doi: 10.1186/s12964-021-00750-x.
7
Hepatic HuR protects against the pathogenesis of non-alcoholic fatty liver disease by targeting PTEN.肝 HuR 通过靶向 PTEN 来防止非酒精性脂肪性肝病的发病机制。
Cell Death Dis. 2021 Mar 4;12(3):236. doi: 10.1038/s41419-021-03514-0.
8
Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules.多器官信号转导动员表达免疫检查点分子的肿瘤相关红细胞。
Mol Cancer Res. 2021 Mar;19(3):507-515. doi: 10.1158/1541-7786.MCR-20-0746. Epub 2020 Nov 24.
9
Erythropoietin and its derivatives: from tissue protection to immune regulation.促红细胞生成素及其衍生物：从组织保护到免疫调节。
Cell Death Dis. 2020 Feb 3;11(2):79. doi: 10.1038/s41419-020-2276-8.
10
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer.血管生成拟态与曲妥珠单抗耐药的 HER2 阳性乳腺癌相关。
Breast Cancer Res. 2019 Aug 6;21(1):88. doi: 10.1186/s13058-019-1167-3.
本文引用的文献
1
Molecular predictors of response to trastuzumab and lapatinib in breast cancer.乳腺癌曲妥珠单抗和拉帕替尼反应的分子预测因子。
Nat Rev Clin Oncol. 2010 Feb;7(2):98-107. doi: 10.1038/nrclinonc.2009.216. Epub 2009 Dec 22.
2
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.不依赖配体的HER2/HER3/PI3K复合物被曲妥珠单抗破坏，并被PI3K抑制剂GDC-0941有效抑制。
Cancer Cell. 2009 May 5;15(5):429-40. doi: 10.1016/j.ccr.2009.03.020.
3
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.重组人促红细胞生成素与癌症患者死亡率：随机试验的荟萃分析
Lancet. 2009 May 2;373(9674):1532-42. doi: 10.1016/S0140-6736(09)60502-X.
4
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.促红细胞生成素刺激剂治疗癌症相关性贫血的利弊：一项荟萃分析。
CMAJ. 2009 May 26;180(11):E62-71. doi: 10.1503/cmaj.090470. Epub 2009 Apr 30.
5
Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis.促红细胞生成素可促进缺乏其受体的肿瘤生长，并通过增强血管生成降低荷瘤小鼠的存活率。
Neoplasia. 2008 Sep;10(9):932-9. doi: 10.1593/neo.08140.
6
Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab.缺氧诱导因子-1α下调在介导抗表皮生长因子受体单克隆抗体西妥昔单抗的抗肿瘤活性中的作用
Mol Cancer Ther. 2008 May;7(5):1207-17. doi: 10.1158/1535-7163.MCT-07-2187.
7
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.一种功能遗传学方法确定PI3K通路是乳腺癌中曲妥珠单抗耐药的主要决定因素。
Cancer Cell. 2007 Oct;12(4):395-402. doi: 10.1016/j.ccr.2007.08.030.
8
Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression.促红细胞生成素阻断可抑制肿瘤血管生成和进展。
PLoS One. 2007 Jun 20;2(6):e549. doi: 10.1371/journal.pone.0000549.
9
Erythropoietin biology in cancer.癌症中的促红细胞生成素生物学
Clin Cancer Res. 2006 Jan 15;12(2):332-9. doi: 10.1158/1078-0432.CCR-05-1771.
10
Trastuzumab in the treatment of breast cancer.曲妥珠单抗治疗乳腺癌
N Engl J Med. 2005 Oct 20;353(16):1734-6. doi: 10.1056/NEJMe058196.
Zotero 插件